Sphera Funds Management’s Cellectar Biosciences CLRB Stock Holding History

Sphera Funds Management’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-292	Closed	-$182K	–	180
2020 Q4	$182K	Hold	292	–	–	0.02%	108
2020 Q3	$109K	Hold	292	–	–	0.01%	95
2020 Q2	$112K	Hold	292	–	–	0.01%	86
2020 Q1	$111K	Hold	292	–	–	0.01%	78
2019 Q4	$197K	Hold	292	–	–	0.02%	86
2019 Q3	$175K	Hold	292	–	–	0.03%	80
2019 Q2	$191K	Hold	292	–	–	0.03%	88
2019 Q1	$206K	Hold	292	–	–	0.02%	104
2018 Q4	$136K	Hold	292	–	–	0.02%	100
2018 Q3	$263K	Buy	+292	New	+$344K	0.03%	108

Other funds holding CLRB

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Sphera Funds Management's CLRB Position: Q1 2021 in Review

Sphera Funds Management sold out of Cellectar Biosciences (CLRB) in Q1 2021, closing a stake of 292 shares — an estimated $182K sold.

Sphera Funds Management first reported a position in CLRB in Q3 2018 and held it in 10 quarters. The position peaked at $263K in Q3 2018. 44 funds tracked by Wall St. Rank hold CLRB as of Q1 2021.

Sphera Funds Management reported no remaining Cellectar Biosciences position as of Q1 2021 after selling out during the quarter.
Sphera Funds Management sold 292 Cellectar Biosciences shares in Q1 2021, an estimated $182K.
Sphera Funds Management first reported a position in Cellectar Biosciences in Q3 2018 and held it in 10 quarters.
Sphera Funds Management's Cellectar Biosciences position peaked at $263K in Q3 2018.
44 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2021.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.